Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

Predictors of and Trends in High-Intensity End-of-Life Care Among Children With Cancer: A Population-Based Study Using Health Services Data Data were pooled from 889 patients who received nivolumab ...

Please provide your email address to receive an email when new articles are posted on . Nivolumab significantly improved RFS for advanced melanoma compared with ipilimumab after 9 years of follow-up.

Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to ipilimumab prolonged survival for patients with advanced melanoma. Nivolumab ...

Patients with wild-type metastatic melanoma that progressed on frontline PD-1 inhibition had almost a 2-year median overall survival (OS) when treated with single-agent ipilimumab (Yervoy), a small ...

Although rare, mucosal melanoma in humans has a low survival rate. It has been difficult to investigate due to a lack of similar cancers in animals for study. Researchers explored a protein common to ...

Vulvar mucosal melanoma is a form of cancer that develops in the cells of the mucus membranes in the vulva. Symptoms include unexpected bleeding, vaginal pain, unusual discharge, itching, and a lump ...

Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced ...

In 2011, the first in a new generation of anticancer drugs called checkpoint inhibitors was approved. The drug, known as ipilimumab or Yervoy, stood apart from standard cancer treatments. It worked by ...